PolyPid is a developer of a polymer lipid-based technology created to extend the release of drugs to prevent infection.
PolyPid’s technology is a clinical state, emerging pharmaceutical process that is developing, manufacturing and eventually commercializing products based on its proprietary polymer-lipid encapsulation matrix platform and is focused on infection treatment and prevention, beginning with treatment of surgical site infections, enabling clients to improve patient outcomes and offer efficient treatment.
Arc investment: 2016
PolyPid Announces the Initiation of a Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Sternal Wound Infection Post-cardiac Surgery
/PRNewswire/ — PolyPid Ltd., a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release…